Vascular endothelial growth factor-D: signaling mechanisms, biology, and clinical relevance

References

• Achen MG, Stacker SA. 2008. Molecular control of lymphatic metastasis. Ann NY Acad Sci. 1131:225–234.
   PubMed Web of Science ®Google Scholar
• Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA. 1998. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA. 95:548–553.
   PubMed Web of Science ®Google Scholar
• Achen MG, Roufail S, Domagala T, Catimel B, Nice EC, Geleick DM, Murphy R, Scott AM, Caesar C, Makinen T, Alitalo K, Stacker SA. 2000. Monoclonal antibodies to vascular endothelial growth factor-D block interactions with both VEGF receptor-2 and VEGF receptor-3. Eur J Biochem. 267:2505–2515.
   PubMedGoogle Scholar
• Achen MG, Williams RA, Minekus MP, Thornton GE, Stenvers K, Rogers PA, Lederman F, Roufail S, Stacker SA. 2001. Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis. J Pathol. 193:147–154.
   PubMedGoogle Scholar
• Achen MG, McColl BK, Stacker SA. 2005. Focus on lymphangiogenesis in tumor metastasis. Cancer Cell. 7:121–127.
   PubMed Web of Science ®Google Scholar
• Adams RH, Alitalo K. 2007. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol. 8:464–478.
   PubMed Web of Science ®Google Scholar
• Alam A, Herault JP, Barron P, Favier B, Fons P, Delesque-Touchard N, Senegas I, Laboudie P, Bonnin J, Cassan C, Savi P, Ruggeri B, Carmeliet P, Bono F, Herbert JM. 2004. Heterodimerization with vascular endothelial growth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3 activity. Biochem Biophys Res Commun. 324:909–915.
   PubMedGoogle Scholar
• Algra AM, Rothwell PM. 2012. Effects of regular aspirin on long-term cancer incidence and metastasis: A systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 13:518–527.
   PubMed Web of Science ®Google Scholar
• Anisimov A, Alitalo A, Korpisalo P, Soronen J, Kaijalainen S, Leppanen VM, Jeltsch M, Yla-Herttuala S, Alitalo K. 2009. Activated forms of VEGF-C and VEGF-D provide improved vascular function in skeletal muscle. Circ Res. 104:1302–1312.
   PubMed Web of Science ®Google Scholar
• Artenstein AW, Opal SM. 2011. Proprotein convertases in health and disease. New Engl J Med. 365:2507–2518.
   PubMed Web of Science ®Google Scholar
• Avantaggiato V, Orlandini M, Acampora D, Oliviero S, Simeone A. 1998. Embryonic expression pattern of the murine figf gene, a growth factor belonging to platelet-derived growth factor/vascular endothelial growth factor family. Mech Dev. 73:221–224.
   PubMed Web of Science ®Google Scholar
• Baldwin ME, Catimel B, Nice EC, Roufail S, Hall NE, Stenvers KL, Karkkainen MJ, Alitalo K, Stacker SA, Achen MG. The specificity of receptor binding by vascular endothelial growth factor-D is different in mouse and man. J Biol Chem. 2001a; 276:19166–19171.
   PubMed Web of Science ®Google Scholar
• Baldwin ME, Roufail S, Halford MM, Alitalo K, Stacker SA, Achen MG. Multiple forms of mouse vascular endothelial growth factor-D are generated by RNA splicing and proteolysis. J Biol Chem. 2001b; 276:44307–44314.
   PubMed Web of Science ®Google Scholar
• Baldwin ME, Stacker SA, Achen MG. 2002. Molecular control of lymphangiogenesis. Bioessays. 24:1030–1040.
   PubMed Web of Science ®Google Scholar
• Baldwin ME, Halford MM, Roufail S, Williams RA, Hibbs ML, Grail D, Kubo H, Stacker SA, Achen MG. 2005. Vascular endothelial growth factor D is dispensable for development of the lymphatic system. Mol Cell Biol. 25:2441–2449.
   PubMed Web of Science ®Google Scholar
• Baluk P, Tammela T, Ator E, Lyubynska N, Achen MG, Hicklin DJ, Jeltsch M, Petrova TV, Pytowski B, Stacker SA, Yla-Herttuala S, Jackson DG, Alitalo K, McDonald DM. 2005. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest. 115:247–257.
   PubMed Web of Science ®Google Scholar
• Bazigou E, Xie S, Chen C, Weston A, Miura N, Sorokin L, Adams R, Muro AF, Sheppard D, Makinen T. 2009. Integrin-alpha9 is required for fibronectin matrix assembly during lymphatic valve morphogenesis. Dev Cell. 17:175–186.
   PubMed Web of Science ®Google Scholar
• Benedito R, Rocha SF, Woeste M, Zamykal M, Radtke F, Casanovas O, Duarte A, Pytowski B, Adams RH. 2012. Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling. Nature. 484:110–114.
   PubMed Web of Science ®Google Scholar
• Bhardwaj S, Roy H, Gruchala M, Viita H, Kholova I, Kokina I, Achen MG, Stacker SA, Hedman M, Alitalo K, Yla-Herttuala S. 2003. Angiogenic responses of vascular endothelial growth factors in periadventitial tissue. Hum Gene Ther. 14:1451–1562.
   PubMed Web of Science ®Google Scholar
• Byzova TV, Goldman CK, Jankau J, Chen J, Cabrera G, Achen MG, Stacker SA, Carnevale KA, Siemionow M, Deitcher SR, DiCorleto PE. 2002. Adenovirus encoding vascular endothelial growth factor-D induces tissue-specific vascular patterns in vivo. Blood. 99:4434–4442.
   PubMed Web of Science ®Google Scholar
• Cao Y, Linden P, Farnebo J, Cao R, Eriksson A, Kumar V, Qi JH, Claesson-Welsh L, Alitalo K. 1998. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci USA. 95:14389–14394.
   PubMed Web of Science ®Google Scholar
• Caunt M, Mak J, Liang WC, Stawicki S, Pan Q, Tong RK, Kowalski J, Ho C, Reslan HB, Ross J, Berry L, Kasman I, Zlot C, Cheng Z, Le Couter J, Filvaroff EH, Plowman G, Peale F, French D, Carano R, Koch AW, Wu Y, Watts RJ, Tessier-Lavigne M, Bagri A. 2008. Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell. 13:331–342.
   PubMed Web of Science ®Google Scholar
• Chretien M, Seidah NG, Basak A, Mbikay M. 2008. Proprotein convertases as therapeutic targets. Expert Opin Ther Targets. 12:1289–1300.
   PubMed Web of Science ®Google Scholar
• Crawford Y, Ferrara N. 2009. VEGF inhibition: Insights from preclinical and clinical studies. Cell Tissue Res. 335:261–269.
   PubMed Web of Science ®Google Scholar
• Davydova N, Roufail S, Streltsov VA, Stacker SA, Achen MG. 2011. The VD1 neutralizing antibody to vascular endothelial growth factor-D: Binding epitope and relationship to receptor binding. J Mol Biol. 407:581–593.
   PubMed Web of Science ®Google Scholar
• Davydova N, Streltsov VA, Roufail S, Lovrecz GO, Stacker SA, Adams TE, Achen MG. 2012. Preparation of human vascular endothelial growth factor-D for structural and preclinical therapeutic studies. Protein Expr Purif. 82:232–239.
   PubMed Web of Science ®Google Scholar
• Debinski W, Slagle-Webb B, Achen MG, Stacker SA, Tulchinsky E, Gillespie GY, Gibo DM. 2001. VEGF-D is an X-linked/AP-1 regulated putative onco-angiogen in human glioblastoma multiforme. Mol Med. 7:598–608.
   PubMed Web of Science ®Google Scholar
• Dignam SS, Case ST. 1990. Balbiani ring 3 in Chironomus tentans encodes a 185-kDa secretory protein which is synthesized throughout the fourth larval instar. Gene. 88:133–140.
   Google Scholar
• Farnsworth RH, Karnezis T, Shayan R, Matsumoto M, Nowell CJ, Achen MG, Stacker SA. 2011. A role for bone morphogenic protein-4 in vascular endothelial growth factor-D mediated tumor growth, metastasis and vessel remodelling. Cancer Res. 71:6547–6557.
   PubMed Web of Science ®Google Scholar
• Fuster V, Charlton P, Boyd A. 2001. Clinical protocol. A phase IIb, randomized, multicenter, double-blind study of the efficacy and safety of Trinam (EG004) in stenosis prevention at the graft-vein anastomosis site in dialysis patients. Hum Gene Ther. 12:2025–2027.
   Google Scholar
• Girling JE, Donoghue JF, Lederman FL, Cann LM, Achen MG, Stacker SA, Rogers PA. 2010. Vascular endothelial growth factor-D over-expressing tumor cells induce differential effects on uterine vasculature in a mouse model of endometrial cancer. Reprod Biol Endocrinol. 8:84.
   PubMedGoogle Scholar
• Glasgow CG, Avila NA, Lin JP, Stylianou MP, Moss J. 2009. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest. 135:1293–1300.
   PubMed Web of Science ®Google Scholar
• Haiko P, Makinen T, Keskitalo S, Taipale J, Karkkainen MJ, Baldwin ME, Stacker SA, Achen MG, Alitalo K. 2008. Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos. Mol Cell Biol. 28:4843–4850.
   PubMed Web of Science ®Google Scholar
• Hajrasouliha AR, Funaki T, Sadrai Z, Hattori T, Chauhan SK, Dana R. 2012. Vascular endothelial growth factor-C promotes alloimmunity by amplifying antigen-presenting cell maturation and lymphangiogenesis. Invest Ophthalmol Vis Sci. 53:1244–1250.
   Google Scholar
• Halford MM, Tebbutt NC, Desai J, Achen MG, Stacker SA. 2012. Towards the biomarker-guided rational use of anti-angiogenic agents in the treatment of metastatic colorectal cancer. Colorectal Cancer. 1:149–161.
   Google Scholar
• Harris NC, Paavonen K, Davydova N, Roufail S, Sato T, Zhang YF, Karnezis T, Stacker SA, Achen MG. 2011. Proteolytic processing of vascular endothelial growth factor-D is essential for its capacity to promote the growth and spread of cancer. FASEB J. 25:2615–2625.
   PubMed Web of Science ®Google Scholar
• He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, Alitalo K. 2002. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst. 94:819–825.
   PubMed Web of Science ®Google Scholar
• He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, Harding T, Jooss K, Takahashi T, Alitalo K. 2005. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res. 65:4739–4746.
   PubMed Web of Science ®Google Scholar
• Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. 2010. Aspirin intake and survival after breast cancer. J Clin Oncol. 28:1467–1472.
   PubMed Web of Science ®Google Scholar
• Huggenberger R, Ullmann S, Proulx ST, Pytowski B, Alitalo K, Detmar M. 2010. Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation. J Exp Med. 207:2255–2269.
   PubMed Web of Science ®Google Scholar
• Huggenberger R, Siddiqui SS, Brander D, Ullmann S, Zimmermann K, Antsiferova M, Werner S, Alitalo K, Detmar M. 2011. An important role of lymphatic vessel activation in limiting acute inflammation. Blood. 117:4667–4678.
   Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. 2004. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med. 350:2335–2342.
   PubMed Web of Science ®Google Scholar
• Jenkins NA, Woollatt E, Crawford J, Gilbert DJ, Baldwin ME, Sutherland GR, Copeland NG, Achen MG. 1997. Mapping of the gene for vascular endothelial growth factor-D in mouse and man to the X chromosome. Chromosome Res. 5:502–505.
   PubMedGoogle Scholar
• Jia H, Bagherzadeh A, Bicknell R, Duchen MR, Liu D, Zachary I. 2004. Vascular endothelial growth factor (VEGF)-D and VEGF-A differentially regulate KDR-mediated signaling and biological function in vascular endothelial cells. J Biol Chem. 279:36148–36157.
   PubMed Web of Science ®Google Scholar
• Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K. 1996. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt-4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 15:290–298.
   PubMed Web of Science ®Google Scholar
• Joukov V, Sorsa T, Kumar V, Jeltsch M, Claesson-Welsh L, Cao Y, Saksela O, Kalkkinen N, Alitalo K. 1997. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J. 16:3898–3911.
   PubMed Web of Science ®Google Scholar
• Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. 2005. Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 23:3706–3712.
   PubMed Web of Science ®Google Scholar
• Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, Jeltsch M, Jackson DG, Talikka M, Rauvala H, Betsholtz C, Alitalo K. 2004. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol. 5:74–80.
   PubMed Web of Science ®Google Scholar
• Karnezis T, Shayan R, Caesar C, Roufail S, Harris NC, Ardipradja K, Zhang YF, Williams SP, Farnsworth RH, Chai MG, Rupasinghe TW, Tull DL, Baldwin ME, Sloan EK, Fox SB, Achen MG, Stacker SA. 2012. VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. Cancer Cell. 21:181–195.
   PubMed Web of Science ®Google Scholar
• Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Yla-Herttuala S, Jaattela M, Alitalo K. 2001. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res. 61:1786–1790.
   PubMed Web of Science ®Google Scholar
• Karpanen T, Heckman CA, Keskitalo S, Jeltsch M, Ollila H, Neufeld G, Tamagnone L, Alitalo K. Functional interaction of VEGF-C and VEGF-D with neuropilin receptors. FASEB J. 2006a; 20:1462–1472.
   PubMed Web of Science ®Google Scholar
• Karpanen T, Wirzenius M, Makinen T, Veikkola T, Haisma HJ, Achen MG, Stacker SA, Pytowski B, Yla-Herttuala S, Alitalo K. Lymphangiogenic growth factor responsiveness is modulated by postnatal lymphatic vessel maturation. Am J Pathol. 2006b; 169:708–718.
   PubMed Web of Science ®Google Scholar
• Kholova I, Koota S, Kaskenpaa N, Leppanen P, Narvainen J, Kavec M, Rissanen TT, Hazes T, Korpisalo P, Grohn O, Yla-Herttuala S. 2007. Adenovirus-mediated gene transfer of human vascular endothelial growth factor-D induces transient angiogenic effects in mouse hind limb muscle. Hum Gene Ther. 18:232–244.
   Google Scholar
• Koch M, Dettori D, Van Nuffelen A, Souffreau J, Marconcini L, Wallays G, Moons L, Bruyere F, Oliviero S, Noel A, Foidart JM, Carmeliet P, Dewerchin M. 2009. VEGF-D deficiency in mice does not affect embryonic or postnatal lymphangiogenesis but reduces lymphatic metastasis. J Pathol. 219:356–364.
   Google Scholar
• Koch S, Tugues S, Li X, Gualandi L, Claesson-Welsh L. 2011. Signal transduction by vascular endothelial growth factor receptors. Biochem J. 437:169–183.
   PubMed Web of Science ®Google Scholar
• Kopfstein L, Veikkola T, Djonov VG, Baeriswyl V, Schomber T, Strittmatter K, Stacker SA, Achen MG, Alitalo K, Christofori G. 2007. Distinct roles of vascular endothelial growth factor-D in lymphangiogenesis and metastasis. Am J Pathol. 170:1348–1361.
   PubMed Web of Science ®Google Scholar
• Kumasaka T, Seyama K, Mitani K, Sato T, Souma S, Kondo T, Hayashi S, Minami M, Uekusa T, Fukuchi Y, Suda K. 2004. Lymphangiogenesis in lymphangioleiomyomatosis: Its implication in the progression of lymphangioleiomyomatosis. Am J Surg Pathol. 28:1007–1016.
   PubMed Web of Science ®Google Scholar
• Kumasaka T, Seyama K, Mitani K, Souma S, Kashiwagi S, Hebisawa A, Sato T, Kubo H, Gomi K, Shibuya K, Fukuchi Y, Suda K. 2005. Lymphangiogenesis-mediated shedding of LAM cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis. Am J Surg Pathol. 29:1356–1366.
   PubMed Web of Science ®Google Scholar
• Laakkonen P, Waltari M, Holopainen T, Takahashi T, Pytowski B, Steiner P, Hicklin D, Persaud K, Tonra JR, Witte L, Alitalo K. 2007. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res. 67:593–599.
   PubMed Web of Science ®Google Scholar
• Lahteenvuo M, Honkonen K, Tervala T, Tammela T, Suominen E, Lahteenvuo J, Kholova I, Alitalo K, Yla-Herttuala S, Saaristo A. 2011. Growth factor therapy and autologous lymph node transfer in lymphedema. Circulation. 123:613–620.
   PubMed Web of Science ®Google Scholar
• Leppanen P, Koota S, Kholova I, Koponen J, Fieber C, Eriksson U, Alitalo K, Yla-Herttuala S. 2005. Gene transfers of vascular endothelial growth factor-A, vascular endothelial growth factor-B, vascular endothelial growth factor-C, and vascular endothelial growth factor-D have no effects on atherosclerosis in hypercholesterolemic low-density lipoprotein-receptor/apolipoprotein B48-deficient mice. Circulation. 112:1347–1352.
   PubMed Web of Science ®Google Scholar
• Leppanen VM, Prota AE, Jeltsch M, Anisimov A, Kalkkinen N, Strandin T, Lankinen H, Goldman A, Ballmer-Hofer K, Alitalo K. 2010. Structural determinants of growth factor binding and specificity by VEGF receptor 2. Proc Natl Acad Sci USA. 107:2425–2430.
   PubMedGoogle Scholar
• Leppanen VM, Jeltsch M, Anisimov A, Tvorogov D, Aho K, Kalkkinen N, Toivanen P, Yla-Herttuala S, Ballmer-Hofer K, Alitalo K. 2011. Structural determinants of vascular endothelial growth factor-D receptor binding and specificity. Blood. 117:1507–1515.
   PubMed Web of Science ®Google Scholar
• Liang WC, Dennis MS, Stawicki S, Chanthery Y, Pan Q, Chen Y, Eigenbrot C, Yin J, Koch AW, Wu X, Ferrara N, Bagri A, Tessier-Lavigne M, Watts RJ, Wu Y. 2007. Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library. J Mol Biol. 366:815–829.
   PubMed Web of Science ®Google Scholar
• Lin J, Lalani AS, Harding TC, Gonzalez M, Wu WW, Luan B, Tu GH, Koprivnikar K, VanRoey MJ, He Y, Alitalo K, Jooss K. 2005. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res. 65:6901–6909.
   PubMed Web of Science ®Google Scholar
• Makinen T, Jussila L, Veikkola T, Karpanen T, Kettunen MI, Pulkkanen KJ, Kauppinen R, Jackson DG, Kubo H, Nishikawa S, Yla-Herttuala S, Alitalo K. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med.. 2001a; 7:199–205.
   PubMed Web of Science ®Google Scholar
• Makinen T, Veikkola T, Mustjoki S, Karpanen T, Catimel B, Nice EC, Wise L, Mercer A, Kowalski H, Kerjaschki D, Stacker SA, Achen MG, Alitalo K. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J. 2001b; 20:4762–4773.
   PubMed Web of Science ®Google Scholar
• Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, Banerji S, Huarte J, Montesano R, Jackson DG, Orci L, Alitalo K, Christofori G, Pepper MS. 2001. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 20:672–682.
   PubMed Web of Science ®Google Scholar
• Marconcini L, Marchio S, Morbidelli L, Cartocci E, Albini A, Ziche M, Bussolino F, Oliviero S. 1999. c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro. Proc Natl Acad Sci USA. 96:9671–9676.
   PubMed Web of Science ®Google Scholar
• McColl BK, Baldwin ME, Roufail S, Freeman C, Moritz RL, Simpson RJ, Alitalo K, Stacker SA, Achen MG. 2003. Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D. J Exp Med. 198:863–868.
   PubMed Web of Science ®Google Scholar
• McColl BK, Paavonen K, Karnezis T, Harris NC, Davydova N, Rothacker J, Nice EC, Harder KW, Roufail S, Hibbs ML, Rogers PA, Alitalo K, Stacker SA, Achen MG. 2007. Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2. FASEB J. 21:1088–1098.
   PubMed Web of Science ®Google Scholar
• McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP3rd, Goldberg HJ, Young LR, Kinder BW, Downey GP, Sullivan EJ, Colby TV, McKay RT, Cohen MM, Korbee L, Taveira-DaSilva AM, Lee HS, Krischer JP, Trapnell BC. 2011. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. New Engl J Med. 364:1595–1606.
   PubMed Web of Science ®Google Scholar
• McDonald NQ, Hendrickson WA. 1993. A structural superfamily of growth factors containing a cystine knot motif. Cell. 73:421–424.
   PubMed Web of Science ®Google Scholar
• Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Moller NP, Risau W, Ullrich A. 1993. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell. 72:835–846.
   PubMed Web of Science ®Google Scholar
• Mitani K, Kumasaka T, Takemura H, Hayashi T, Gunji Y, Kunogi M, Akiyoshi T, Takahashi K, Suda K, Seyama K. 2009. Cytologic, immunocytochemical and ultrastructural characterization of lymphangioleiomyomatosis cell clusters in chylous effusions of patients with lymphangioleiomyomatosis. Acta Cytol. 53:402–409.
   PubMed Web of Science ®Google Scholar
• Ny A, Koch M, Vandevelde W, Schneider M, Fischer C, Diez-Juan A, Neven E, Geudens I, Maity S, Moons L, Plaisance S, Lambrechts D, Carmeliet P, Dewerchin M. 2008. Role of VEGF-D and VEGFR-3 in developmental lymphangiogenesis, a chemicogenetic study in Xenopus tadpoles. Blood. 112:1740–1749.
   PubMed Web of Science ®Google Scholar
• Orlandini M, Oliviero S. 2001. In fibroblasts Vegf-D expression is induced by cell-cell contact mediated by cadherin-11. J Biol Chem. 276:6576–6581.
   PubMed Web of Science ®Google Scholar
• Orlandini M, Marconcini L, Ferruzzi R, Oliviero S. 1996. Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family. Proc Natl Acad Sci USA. 93:11675–11680.
   PubMed Web of Science ®Google Scholar
• Orlandini M, Semboloni S, Oliviero S. 2003. Beta-catenin inversely regulates vascular endothelial growth factor-D mRNA stability. J Biol Chem. 278:44650–44656.
   PubMed Web of Science ®Google Scholar
• Orlandini M, Spreafico A, Bardelli M, Rocchigiani M, Salameh A, Nucciotti S, Capperucci C, Frediani B, Oliviero S. 2006. Vascular endothelial growth factor-D activates VEGFR-3 expressed in osteoblasts inducing their differentiation. J Biol Chem. 281:17961–17967.
   PubMed Web of Science ®Google Scholar
• Pan Q, Chanthery Y, Liang WC, Stawicki S, Mak J, Rathore N, Tong RK, Kowalski J, Yee SF, Pacheco G, Ross S, Cheng Z, Le Couter J, Plowman G, Peale F, Koch AW, Wu Y, Bagri A, Tessier-Lavigne M, Watts RJ. 2007. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell. 11:53–67.
   PubMed Web of Science ®Google Scholar
• Partanen TA, Arola J, Saaristo A, Jussila L, Ora A, Miettinen M, Stacker SA, Achen MG, Alitalo K. 2000. VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J. 14:2087–2096.
   PubMed Web of Science ®Google Scholar
• Persaud K, Tille JC, Liu M, Zhu Z, Jimenez X, Pereira DS, Miao HQ, Brennan LA, Witte L, Pepper MS, Pytowski B. 2004. Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human anti-human VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C. J Cell Sci. 117:2745–2756.
   PubMed Web of Science ®Google Scholar
• Pytowski B, Goldman J, Persaud K, Wu Y, Witte L, Hicklin DJ, Skobe M, Boardman KC, Swartz MA. 2005. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. J Natl Cancer Inst. 97:14–21.
   PubMedGoogle Scholar
• Rinderknecht M, Villa A, Ballmer-Hofer K, Neri D, Detmar M. 2010. Phage-derived fully human monoclonal antibody fragments to human vascular endothelial growth factor-C block its interaction with VEGF receptor-2 and 3. PLoS One. 5:e11941.
   PubMed Web of Science ®Google Scholar
• Rissanen TT, Markkanen JE, Gruchala M, Heikura T, Puranen A, Kettunen MI, Kholova I, Kauppinen RA, Achen MG, Stacker SA, Alitalo K, Yla-Herttuala S. 2003. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res. 92:1098–1106.
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, Meade TW. 2010. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 376:1741–1750.
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. 2011. Effect of daily aspirin on long-term risk of death due to cancer: Analysis of individual patient data from randomised trials. Lancet. 377:31–41.
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. 2012. Effect of daily aspirin on risk of cancer metastasis: A study of incident cancers during randomised controlled trials. Lancet. 379:1591–1601.
   PubMed Web of Science ®Google Scholar
• Roy H, Bhardwaj S, Babu M, Lahteenvuo JE, Yla-Herttuala S. 2010. VEGF-DdeltaNdeltaC mediated angiogenesis in skeletal muscles of diabetic WHHL rabbits. Eur J Clin Invest. 40:422–432.
   Google Scholar
• Rutanen J, Leppanen P, Tuomisto TT, Rissanen TT, Hiltunen MO, Vajanto I, Niemi M, Hakkinen T, Karkola K, Stacker SA, Achen MG, Alitalo K, Yla-Herttuala S. 2003. Vascular endothelial growth factor-D expression in human atherosclerotic lesions. Cardiovasc Res. 59:971–979.
   PubMed Web of Science ®Google Scholar
• Rutanen J, Rissanen TT, Markkanen JE, Gruchala M, Silvennoinen P, Kivela A, Hedman A, Hedman M, Heikura T, Orden MR, Stacker SA, Achen MG, Hartikainen J, Yla-Herttuala S. 2004. Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart. Circulation. 109:1029–1035.
   PubMed Web of Science ®Google Scholar
• Rutanen J, Turunen AM, Teittinen M, Rissanen TT, Heikura T, Koponen JK, Gruchala M, Inkala M, Jauhiainen S, Hiltunen MO, Turunen MP, Stacker SA, Achen MG, Yla-Herttuala S. 2005. Gene transfer using the mature form of VEGF-D reduces neointimal thickening through nitric oxide-dependent mechanism. Gene Ther. 12:980–987.
   PubMed Web of Science ®Google Scholar
• Schafer G, Wissmann C, Hertel J, Lunyak V, Hocker M. 2008. Regulation of vascular endothelial growth factor D by orphan receptors hepatocyte nuclear factor-4 alpha and chicken ovalbumin upstream promoter transcription factors 1 and 2. Cancer Res. 68:457–466.
   Google Scholar
• Schoppmann SF, Birner P, Stockl J, Kalt R, Ullrich R, Caucig C, Kriehuber E, Nagy K, Alitalo K, Kerjaschki D. 2002. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol. 161:947–956.
   PubMed Web of Science ®Google Scholar
• Seyama K, Kumasaka T, Souma S, Sato T, Kurihara M, Mitani K, Tominaga S, Fukuchi Y. 2006. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol. 4:143–152.
   PubMedGoogle Scholar
• Seyama K, Kumasaka T, Kurihara M, Mitani K, Sato T. 2010. Lymphangioleiomyomatosis: A disease involving the lymphatic system. Lymphat Res Biol. 8:21–31.
   Google Scholar
• Shayan R, Achen MG, Stacker SA. 2006. Lymphatic vessels in cancer metastasis: Bridging the gaps. Carcinogenesis. 27:1729–1738.
   PubMed Web of Science ®Google Scholar
• Shayan R, Karnezis T, Tsantikos E, Williams SP, Runting A, Ashton MW, Achen MG, Hibbs ML, Stacker SA. 2007. A system for quantifying the patterning of the lymphatic vasculature. Growth Factors. 25:417–425.
   Web of Science ®Google Scholar
• Siegfried G, Basak A, Cromlish JA, Benjannet S, Marcinkiewicz J, Chretien M, Seidah NG, Khatib AM. 2003. The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis. J Clin Invest. 111:1723–1732.
   PubMed Web of Science ®Google Scholar
• Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. 1998. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 92:735–745.
   PubMed Web of Science ®Google Scholar
• Song M, Yang H, Yao S, Ma F, Li Z, Deng Y, Deng H, Zhou Q, Lin S, Wei Y. 2007. A critical role of vascular endothelial growth factor D in zebrafish embryonic vasculogenesis and angiogenesis. Biochem Biophys Res Commun. 357:924–930.
   PubMedGoogle Scholar
• Stacker SA, Achen MG. 2008. From anti-angiogenesis to anti-lymphangiogenesis: Emerging trends in cancer therapy. Lymphat Res Biol. 6:165–172.
   PubMedGoogle Scholar
• Stacker SA, Stenvers K, Caesar C, Vitali A, Domagala T, Nice E, Roufail S, Simpson RJ, Moritz R, Karpanen T, Alitalo K, Achen MG. Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. J Biol Chem. 1999a; 274:32127–32136.
   PubMed Web of Science ®Google Scholar
• Stacker SA, Vitali A, Caesar C, Domagala T, Groenen LC, Nice E, Achen MG, Wilks AF. A mutant form of vascular endothelial growth factor (VEGF) that lacks VEGF receptor-2 activation retains the ability to induce vascular permeability. J Biol Chem. 1999b; 274:34884–34892.
   PubMed Web of Science ®Google Scholar
• Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H, Achen MG. 2001. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med.. 7:186–191.
   PubMed Web of Science ®Google Scholar
• Stacker SA, Williams RA, Achen MG. 2004. Lymphangiogenic growth factors as markers of tumor metastasis. APMIS. 112:539–549.
   PubMed Web of Science ®Google Scholar
• Tammela T, Alitalo K. 2010. Lymphangiogenesis: Molecular mechanisms and future promise. Cell. 140:460–476.
   PubMed Web of Science ®Google Scholar
• Tammela T, Saaristo A, Holopainen T, Lyytikka J, Kotronen A, Pitkonen M, Abo-Ramadan U, Yla-Herttuala S, Petrova TV, Alitalo K. 2007. Therapeutic differentiation and maturation of lymphatic vessels after lymph node dissection and transplantation. Nat Med. 13:1458–1466.
   PubMed Web of Science ®Google Scholar
• Tammela T, Zarkada G, Wallgard E, Murtomaki A, Suchting S, Wirzenius M, Waltari M, Hellstrom M, Schomber T, Peltonen R, Freitas C, Duarte A, Isoniemi H, Laakkonen P, Christofori G, Yla-Herttuala S, Shibuya M, Pytowski B, Eichmann A, Betsholtz C, Alitalo K. 2008. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature. 454:656–660.
   PubMed Web of Science ®Google Scholar
• Tammela T, Zarkada G, Nurmi H, Jakobsson L, Heinolainen K, Tvorogov D, Zheng W, Franco CA, Murtomaki A, Aranda E, Miura N, Yla-Herttuala S, Fruttiger M, Makinen T, Eichmann A, Pollard JW, Gerhardt H, Alitalo K. 2011. VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling. Nat Cell Biol. 13:1202–1213.
   PubMed Web of Science ®Google Scholar
• Thelen A, Scholz A, Benckert C, von Marschall Z, Schroder M, Wiedenmann B, Neuhaus P, Rosewicz S, Jonas S. 2008. VEGF-D promotes tumor growth and lymphatic spread in a mouse model of hepatocellular carcinoma. Int J Cancer. 122:2471–2481.
   Google Scholar
• Toivanen PI, Nieminen T, Viitanen L, Alitalo A, Roschier M, Jauhiainen S, Markkanen JE, Laitinen OH, Airenne TT, Salminen TA, Johnson MS, Airenne KJ, Yla-Herttuala S. 2009. Novel vascular endothelial growth factor D variants with increased biological activity. J Biol Chem. 284:16037–16048.
   PubMed Web of Science ®Google Scholar
• Veikkola T, Jussila L, Makinen T, Karpanen T, Jeltsch M, Petrova TV, Kubo H, Thurston G, McDonald DM, Achen MG, Stacker SA, Alitalo K. 2001. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J. 20:1223–1231.
   PubMed Web of Science ®Google Scholar
• Vlahakis NE, Young BA, Atakilit A, Sheppard D. 2005. The lymphangiogenic vascular endothelial growth factors VEGF-C and -D are ligands for the integrin alpha9beta1. J Biol Chem. 280:4544–4552.
   PubMed Web of Science ®Google Scholar
• Von Marschall Z, Scholz A, Stacker SA, Achen MG, Jackson DG, Alves F, Schirner M, Haberey M, Thierauch KH, Wiedenmann B, Rosewicz S. 2005. Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer. Int J Oncol. 27:669–679.
   Google Scholar
• Wang JF, Zhang XF, Groopman JE. 2001. Stimulation of beta1 integrin induces tyrosine phosphorylation of vascular endothelial growth factor receptor-3 and modulates cell migration. J Biol Chem. 276:41950–41957.
   PubMedGoogle Scholar
• Weickhardt AJ, Williams D, Lee C, Simes J, Murone C, Wilson K, Cummins M, Asadi K, Price TJ, Mariadason J, Tebbutt NC. 2011. Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study. In: 2011 ASCO Annual Meeting. J Clin Oncol. 29 2011 (Suppl abstr 3531).
   Google Scholar
• White JD, Hewett PW, Kosuge D, McCulloch T, Enholm BC, Carmichael J, Murray JC. 2002. Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. Cancer Res. 62:1669–1675.
   PubMed Web of Science ®Google Scholar
• Wiesmann C, Fuh G, Christinger HW, Eigenbrot C, Wells JA, de Vos AM. 1997. Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell. 91:695–704.
   PubMed Web of Science ®Google Scholar
• Wirzenius M, Tammela T, Uutela M, He Y, Odorisio T, Zambruno G, Nagy JA, Dvorak HF, Yla-Herttuala S, Shibuya M, Alitalo K. 2007. Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting. J Exp Med. 204:1431–1440.
   PubMed Web of Science ®Google Scholar
• Wise LM, Ueda N, Dryden NH, Fleming SB, Caesar C, Roufail S, Achen MG, Stacker SA, Mercer AA. 2003. Viral vascular endothelial growth factors vary extensively in amino acid sequence, receptor-binding specificities, and the ability to induce vascular permeability yet are uniformly active mitogens. J Biol Chem. 278:38004–38014.
   PubMed Web of Science ®Google Scholar
• Witte L, Hicklin DJ, Zhu Z, Pytowski B, Kotanides H, Rockwell P, Bohlen P. 1998. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev. 17:155–161.
   PubMed Web of Science ®Google Scholar
• Xu Y, Yuan L, Mak J, Pardanaud L, Caunt M, Kasman I, Larrivee B, Del Toro R, Suchting S, Medvinsky A, Silva J, Yang J, Thomas JL, Koch AW, Alitalo K, Eichmann A, Bagri A. 2010. Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. J Cell Biol. 188:115–130.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Nezu JI, Shimane M, Hirata Y. 1997. Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. Genomics. 42:483–488.
   PubMed Web of Science ®Google Scholar
• Yokoyama Y, Charnock-Jones DS, Licence D, Yanaihara A, Hastings JM, Holland CM, Emoto M, Umemoto M, Sakamoto T, Sato S, Mizunuma H, Smith SK. 2003. Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. Br J Cancer. 88:237–244.
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Endo Y, Tabata K, Kawamura T, Yun HY, Bandou E, Sasaki T, Miura M. 2005. Role of VEGF-C and VEGF-D in lymphangiogenesis in gastric cancer. Int J Clin Oncol. 10:318–327.
   Google Scholar
• Young LR, Vandyke R, Gulleman PM, Inoue Y, Brown KK, Schmidt LS, Linehan WM, Hajjar F, Kinder BW, Trapnell BC, Bissler JJ, Franz DN, McCormack FX. 2010. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest. 138:674–681.
   PubMed Web of Science ®Google Scholar
• Zhang H, Li Y, Li H, Bassi R, Jimenez X, Witte L, Bohlen P, Hicklin D, Zhu Z. 2004. Inhibition of both the autocrine and the paracrine growth of human leukemia with a fully human antibody directed against vascular endothelial growth factor receptor 2. Leuk Lymphoma. 45:1887–1897.
   PubMed Web of Science ®Google Scholar